Phase 2 Lung Cancer Trial, Recruiting NCT06165419 Sponsor: Stony Brook University Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06165419
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a solid tumor (a type of cancer that forms a lump or mass) that did not start in the brain or spinal cord, and where the cancer has spread to other parts of the body, confirmed by scans or tissue testing
  • People whose cancer has spread to the spine, as shown on medical imaging
  • People where the affected area of the spine involves no more than 3 vertebrae (bones in the spine) that are next to each other
  • People whose nervous system is working normally, or who have only minor weakness in their muscles (muscle strength rated 4 or 5 out of 5), whether or not they are taking steroid medication
  • People who have been assessed by both a radiation oncology specialist and a spine surgeon or neurosurgeon
  • People with a general health and activity level rated between 0 and 3 on a standard medical scale (where 0 means fully active and 3 means limited self-care ability) (confirm with trial site)

Who may not be able to join:

  • People whose spine is considered unstable based on a specialist scoring system called the Spinal Instability Neoplastic Score (SINS), where a score above 12 indicates the spine may not be stable enough for this trial
  • People who have already had surgery or radiation treatment directed at the specific area of the spine being studied in this trial
  • People whose cancer type is known to respond well to standard radiation, such as small cell lung cancer, lymphoma, multiple myeloma, or germ-cell tumors

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Kartik Mani, MD PhD, Stony Brook Cancer Center

Phone: 631-216-2990

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Stony Brook University
Registry
ClinicalTrials.gov
Start date
14 December 2023
Est. completion
31 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Cumulative incidence of spinal surgery/stabilization within 6 months following SBRT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov